HERON client summit produces clear connection between strong evidence and sound strategy
Recent meetings with a number of HERON’s global pharmaceutical and biotechnology clients were held to discuss the relationship between strong evidence and sound market access strategies. Reflecting on the import of both in the successful commercialization of new products, a number of clients cited internal organization as a potential obstacle to leveraging important evidence/information between product team members from HEOR to marketing, product commercialization, business development and other departments.
HERON supports commercial decision-making from early landscape assessment to pricing strategies and launch sequencing. In that capacity, we realize the productive gain from streamlined internal (product/portfolio team) communications and offer customized training and workshops geared to that end. Internal stakeholder reporting based on smart synthesis and predictable information flow are key and HERON is happy to discuss this process with interested parties.
HERON’s guide to strong evidence
The links below go to brief (3 minute) HERON webinar demonstrations on the role and import of evidence generation and synthesis, health economic modelling and data analytics, and global value dossiers, in the definition, substantiation and articulation of product value. HERON clients have found this information very useful as they engage us in early phase commercial planning:
- Evidence Review and Synthesis – Sam Stoddart, VP Scientific Affairs
- Economic Evaluation – Prof. John Posnett, SVP Health Economic Modelling Unit
- Global Value Dossiers – Dr. Ebony Samuels, VP Strategic Communications and Compliance